Vaccine candidate against COVID-19
BriLife , also known as IIBR-100 , is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[ 1] [ 2] [ 3] [ 4] It was developed by the Israel Institute for Biological Research (IIBR).[ 1] [ 5] [ 6] The IIBR partnered with the US -based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[ 7] [ 8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[ 9] [ 3]
References
^ a b Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines" . Theranostics . 11 (4): 1690–1702. doi :10.7150/thno.53691 . PMC 7778607 . PMID 33408775 .
^ Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19" . Frontiers in Molecular Biosciences . 8 : 635337. doi :10.3389/fmolb.2021.635337 . PMC 8082173 . PMID 33937326 .
^ a b Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic" . Advanced Drug Delivery Reviews . 170 : 113–141. doi :10.1016/j.addr.2021.01.003 . PMC 7789827 . PMID 33422546 .
^ Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials" . Frontiers in Molecular Biosciences . 8 : 637378. doi :10.3389/fmolb.2021.637378 . PMC 8219860 . PMID 34179072 .
^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
^ Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19" . International Journal of Infectious Diseases . 104 : 441–451. doi :10.1016/j.ijid.2021.01.035 . PMC 7816887 . PMID 33476760 .
^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine" . Reuters . Retrieved 10 November 2021 .
^ "Israeli-produced vaccine shipped to Georgia for Phase II trial" . i24 News . 15 August 2021. Retrieved 10 November 2021 .
^ Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge" . Nature Communications . 11 (1): 6402. doi :10.1038/s41467-020-20228-7 . PMC 7745033 . PMID 33328475 .
External links
Development Classes Administration Vaccines
Inventors/ researchers Controversy Related
Institutions
Hospitals and medical clinics
Organizations
Health institutes Pandemic institutes Relief funds
Data (templates)
Global Africa Americas Asia Europe Oceania Others